ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.